Osteoarthritis in dogs: intra-articular adipose-derived stem cells vs placebo — MAYBE (weak evidence)

In dogs with osteoarthritis, does intra-articular adipose-derived stem cell therapy improve function vs placebo injection?

Shelf #186 · gate-verified and displayed under the developer's blinded-trial rule

MAYBE (weak evidence): The evidence for intra-articular adipose-derived stem cells in canine osteoarthritis is one placebo-controlled trial and one uncontrolled case series, both from the therapy's commercial provider. Black 2007 (hip) is a genuine randomised, double-blinded, multicentre, controlled trial reporting significantly improved lameness and combined lameness/pain/range-of-motion scores vs controls — but its record's abstract states no dog numbers and no effect sizes, so the size of any benefit cannot be carded. Black 2008 (elbow) is not controlled evidence: its record describes 14 treated dogs followed for 180 days, with significant improvement against baseline, and does not establish randomisation, blinding, or a control group. Significant-sounding results, no measurable magnitude, provider-run: that is weak evidence, and the stamp says so. Drafted Nov 10, 2026 (VetMed build, topic #186); all figures from abstracts fetched and verified at drafting.

Black 2007 (hip): stem-cell treated dogs improved significantly on lameness and combined scores vs controls — the record reports no effect sizes

Randomised, double-blinded, multicentre, controlled trial

Who: Dogs: dogs with chronic osteoarthritis of the coxofemoral (hip) joints, given a single intra-articular injection of autologous adipose-derived mesenchymal stem and regenerative cells or control, in a randomized, double-blinded, multicenter, controlled trial. The record's abstract does not state how many dogs were enrolled.

Result: Dogs treated with adipose-derived stem cell therapy had significantly improved scores for lameness, and for the compiled scores for lameness, pain, and range of motion, compared with control dogs. The authors describe this as the first randomized, blinded, placebo-controlled clinical trial reporting on the effectiveness of stem cell therapy in dogs. The abstract reports no group sizes, scores, or effect magnitudes, so beyond direction and stated significance, no figure can be carded from this record.

Watch out: An abstract with no numbers at all caps what any shelf can claim from it. The trial was run from Vet-Stem, Inc. — the therapy's commercial provider, and the corresponding author's affiliation on the record — and the therapy had already been commercially available since 2003, before this trial was published.

Black LL, Gaynor J, Gahring D et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther. 2007;8(4):272-284. PMID: 18183546. Registry ID: none in the record. MeSH: Adipose Tissue · Animals · Dogs · Double-Blind Method · Female · Hip Dysplasia, Canine · Injections, Intra-Articular · Lameness, Animal · Male · Mesenchymal Stem Cell Transplantation · Pain Measurement · Severity of Illness Index · Transplantation, Autologous · Treatment Outcome · United States

Black 2008 (elbow): significant improvement on veterinarian-assessed scores over 180 days in 14 dogs — measured against baseline only, as reported

Uncontrolled case series of treated dogs (record does not state randomisation, blinding, or a control group)

Who: Dogs: 14 dogs with chronic osteoarthritis of the humeroradial (elbow) joints, treated with an intra-articular injection of autologous adipose-derived mesenchymal stem cells; veterinarians assessed each dog for lameness, pain on manipulation, range of motion, and functional disability using a numeric rating scale at baseline and at specified intervals up to 180 days after treatment.

Result: Statistically significant improvement in the outcome measures was demonstrated over the follow-up period. The record's abstract gives no scores, no effect sizes, and describes no comparison group, so the improvement carded here is against the dogs' own baselines, exactly as the record reports it.

Watch out: Unlike the hip trial above, this record does not establish randomisation, blinding, or a placebo control — its abstract and publication types describe treated dogs followed over time, so natural fluctuation, concurrent care, and assessor expectation are all unexcluded explanations. Also run from Vet-Stem Inc., the commercial provider (affiliation on the record).

Black LL, Gaynor J, Adams C et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 2008;9(3):192-200. PMID: 19003780. Registry ID: none in the record. MeSH: Animals · Chronic Disease · Dog Diseases · Dogs · Elbow Joint · Female · Injections, Intra-Articular · Lameness, Animal · Male · Mesenchymal Stem Cell Transplantation · Osteoarthritis · Range of Motion, Articular · Time Factors · Transplantation, Autologous · Treatment Outcome

Synthesis: positive-sounding, provider-run, and unquantified — the honest grade is weak evidence

Synthesis

Who: Synthesis of the cards above: Black 2007 (randomised, double-blinded, multicentre, controlled hip trial; enrolment not stated in the record) and Black 2008 (14-dog uncontrolled elbow case series).

Result: The two studies are consistent in direction — veterinarian-assessed lameness, pain, and function scores improved after intra-articular autologous adipose-derived stem cell injection — and the hip study's design (randomised, double-blinded, placebo-controlled, in the authors' own description) is the right design. What is missing is everything needed to size the effect: neither record's abstract reports a single score, group size for the hip trial, or effect magnitude, both studies come from the company selling the therapy, and the elbow study cannot exclude expectation and natural history. A clinician asked 'how much will this help?' cannot be answered from this evidence base.

Watch out: This shelf grades the published record as fetched: fuller numbers may exist in the papers' full texts, but VetMed cards only what the verified record carries. An independent, adequately sized, blinded trial with reported effect sizes would justify rebuilding this shelf at a higher stamp.

Synthesis of Black LL et al. PMID: 18183546; Black LL et al. PMID: 19003780. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.